Product Platform

Our strategy at Alnylam is to lead the translation of the science of RNAi into a robust drug discovery capability and to build a significant product pipeline of innovative medicines that are generated from a proprietary combination of technologies referred to as our "product platform." Our efforts are well underway in a time when the pace of biomedical discovery is faster than ever and the hunger for innovative medicines is greater than ever. And with RNAi technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.

The power and potential of RNAi is that it allows for the targeting of virtually any disease-causing gene in the genome. In order to prioritize our efforts, we focus on disease areas with significant unmet medical need, where the biology around the target is well characterized and understood, and where our delivery technologies can achieve efficient and specific effects. Together with our collaborators, we are working towards developing novel therapeutics that have the potential to intervene in the disease processes of these major unmet medical needs.